{"id":2323,"date":"2017-09-20T11:57:41","date_gmt":"2017-09-20T06:27:41","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2323"},"modified":"2021-07-24T12:56:51","modified_gmt":"2021-07-24T07:26:51","slug":"business-cocktail-13","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-13","title":{"rendered":"Business Cocktail"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0e2a3f310d9\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0e2a3f310d9\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-13\/#Chinese_pharma_company_Shanghai_Fosun_to_acquire_74_stake_in_Indian_company_Gland_Pharma_for_109_billion\" >Chinese pharma company Shanghai Fosun to acquire 74% stake in Indian company Gland Pharma for $1.09 billion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-13\/#Teva_Pharmaceutical_sell_last_of_its_Womens_Health_Portfolio_gains_another_248_billion\" >Teva&nbsp;Pharmaceutical sell last of its Women\u2019s Health Portfolio, gains another $2.48 billion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-13\/#Gates_Foundation_invests_in_Immunocore_to_fuel_infectious_disease_R_D\" >Gates Foundation invests in Immunocore to fuel infectious disease R&amp;D<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-13\/#Disarm_Therapeutics_announces_completion_of_Series_A_funding_of_USD_30_million\" >Disarm Therapeutics announces completion of Series A funding of USD 30 million<\/a><\/li><\/ul><\/nav><\/div>\n<h4 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Chinese_pharma_company_Shanghai_Fosun_to_acquire_74_stake_in_Indian_company_Gland_Pharma_for_109_billion\"><\/span><span style=\"color: #000000;\"><strong>Chinese pharma company Shanghai Fosun to acquire 74% stake in Indian company Gland Pharma for $1.09 billion <\/strong><\/span><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<p>In July last year Chinese company Shanghai Fosun Pharmaceutical announced to acquire 74% per cent stake in Gland Pharma (Hyderabad-based Company) for not more than USD 1.09 billion. Initially the deal was set to acquire 86.08 per cent stake for USD 1.26 billion but it got revised as per the latest regulatory filing of the company.<\/p>\n<h4><span class=\"ez-toc-section\" id=\"Teva_Pharmaceutical_sell_last_of_its_Womens_Health_Portfolio_gains_another_248_billion\"><\/span><span style=\"color: #000000;\">Teva&nbsp;Pharmaceutical sell last of its Women\u2019s Health Portfolio, gains another $2.48 billion<\/span><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<p style=\"text-align: justify;\">To progress repayment of term loan debt Teva Pharmaceutical has recently announced that &nbsp;it has entered into two agreements to sell the remaining resources of its specialty global women\u2019s health business for USD 1.38 billion. Earning from these sales, combined with earnings &nbsp;from the recently announced sale of PARAGARD&nbsp;is around USD 2.48 billion.<\/p>\n<h4 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Gates_Foundation_invests_in_Immunocore_to_fuel_infectious_disease_R_D\"><\/span><span style=\"color: #000000;\"><strong>Gates Foundation invests in Immunocore to fuel infectious disease R&amp;D<\/strong><\/span><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<p style=\"text-align: justify;\">Immunocore which is primarily known for its work in oncology is expanding its horizon into tuberculosis and HIV treatment. Bill &amp; Melinda Gates Foundation is&nbsp;investing&nbsp;up to USD 40 million in Immunocore to fuel its research into the use of T cell receptor (TCR)-based therapeutics to effectively treat tuberculosis and HIV.<\/p>\n<h4 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Disarm_Therapeutics_announces_completion_of_Series_A_funding_of_USD_30_million\"><\/span><span style=\"color: #000000;\"><strong>Disarm Therapeutics announces completion of Series A funding of USD 30 million<\/strong><\/span><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<p style=\"text-align: justify;\">Disarm Therapeutics has recently announced completion of Series A funding of USD 30 million as it looks for a breakthrough approach in axonal degeneration. Funding is led by Atlas Venture and some co-investors like Lightstone Ventures and AbbVie Ventures.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chinese pharma company Shanghai Fosun to acquire 74% stake in Indian company Gland Pharma for $1.09 billion In July last year Chinese company Shanghai Fosun Pharmaceutical announced to acquire 74% per cent stake in Gland Pharma (Hyderabad-based Company) for not more than USD 1.09 billion. Initially the deal was set to acquire 86.08 per cent [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1038,1044,1036,1039,776,204,1040,1042,1045,297,1041,1037,1043,1046,563,585],"industry":[],"therapeutic_areas":[17227,17411],"class_list":["post-2323","post","type-post","status-publish","format-standard","hentry","category-notizia","tag-abbvie-ventures","tag-acquire","tag-atlas-venture","tag-axonal-degeneration","tag-business-cocktail","tag-delveinsight","tag-disarm-therapeutics","tag-gates-foundation","tag-gland-pharma","tag-hiv","tag-immunocore","tag-lightstone-ventures","tag-paragard","tag-shanghai-fosun","tag-teva-pharmaceutical","tag-tuberculosis","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-womens-health"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Shanghai Fosun, Teva Pharmaceutical Business Cocktail<\/title>\n<meta name=\"description\" content=\"Chinese pharma company Shanghai Fosun to acquire 74% stake in Indian company Gland Pharma for $1.09 billion. Teva Pharmaceutical...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-13\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Fosun, Teva Pharmaceutical Business Cocktail\" \/>\n<meta property=\"og:description\" content=\"Chinese pharma company Shanghai Fosun to acquire 74% stake in Indian company Gland Pharma for $1.09 billion. Teva Pharmaceutical...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-13\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-09-20T06:27:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:51+00:00\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Fosun, Teva Pharmaceutical Business Cocktail","description":"Chinese pharma company Shanghai Fosun to acquire 74% stake in Indian company Gland Pharma for $1.09 billion. Teva Pharmaceutical...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-13","og_locale":"en_US","og_type":"article","og_title":"Shanghai Fosun, Teva Pharmaceutical Business Cocktail","og_description":"Chinese pharma company Shanghai Fosun to acquire 74% stake in Indian company Gland Pharma for $1.09 billion. Teva Pharmaceutical...","og_url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-13","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-09-20T06:27:41+00:00","article_modified_time":"2021-07-24T07:26:51+00:00","author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-13","url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-13","name":"Shanghai Fosun, Teva Pharmaceutical Business Cocktail","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"datePublished":"2017-09-20T06:27:41+00:00","dateModified":"2021-07-24T07:26:51+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Chinese pharma company Shanghai Fosun to acquire 74% stake in Indian company Gland Pharma for $1.09 billion. Teva Pharmaceutical...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/business-cocktail-13"]}]},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AbbVie Ventures<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">acquire<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Atlas Venture<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">axonal degeneration<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Business Cocktail<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Disarm Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gates Foundation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gland Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HIV<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Immunocore<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lightstone Ventures<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">PARAGARD<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Shanghai Fosun<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Teva Pharmaceutical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Tuberculosis<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AbbVie Ventures<\/span>","<span class=\"advgb-post-tax-term\">acquire<\/span>","<span class=\"advgb-post-tax-term\">Atlas Venture<\/span>","<span class=\"advgb-post-tax-term\">axonal degeneration<\/span>","<span class=\"advgb-post-tax-term\">Business Cocktail<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Disarm Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Gates Foundation<\/span>","<span class=\"advgb-post-tax-term\">Gland Pharma<\/span>","<span class=\"advgb-post-tax-term\">HIV<\/span>","<span class=\"advgb-post-tax-term\">Immunocore<\/span>","<span class=\"advgb-post-tax-term\">Lightstone Ventures<\/span>","<span class=\"advgb-post-tax-term\">PARAGARD<\/span>","<span class=\"advgb-post-tax-term\">Shanghai Fosun<\/span>","<span class=\"advgb-post-tax-term\">Teva Pharmaceutical<\/span>","<span class=\"advgb-post-tax-term\">Tuberculosis<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Sep 20, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Sep 20, 2017 11:57 am","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2323","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2323"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2323\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2323"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2323"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2323"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2323"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2323"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}